Last reviewed · How we verify
PLENDIL®
At a glance
| Generic name | PLENDIL® |
|---|---|
| Sponsor | Ranbaxy Laboratories Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Felodipine Controlled Release Tablets and Felodipine Sustained Release Tablets in Healthy Subjects Under Fasting State Comparative Pharmacokinetic Study (PHASE1)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Bioequivalence Study of Felodipine ER Tablets 10 mg Under Fasting Conditions (NA)
- Bioequivalence Study of Felodipine ER Tablets 10 mg Under Fed Conditions (NA)
- Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension (PHASE4)
- Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PLENDIL® CI brief — competitive landscape report
- PLENDIL® updates RSS · CI watch RSS
- Ranbaxy Laboratories Limited portfolio CI